Cumulative Mitoxantrone-Induced Haematological and Hepatic Adverse Effects in a Subchronic In vivo Study by Rossato, Luciana G. et al.
Cumulative Mitoxantrone-Induced Haematological and Hepatic
Adverse Effects in a Subchronic In vivo Study
Luciana G. Rossato1, Vera M. Costa1, Eliane Dallegrave1,2, Marcelo Arbo1, Ricardo J. Dinis-Oliveira1,3,4, Alice Santos-Silva5,
Jose A. Duarte6, Maria de Lourdes Bastos1, Carlos Palmeira7 and Fernando Remi~ao1
1REQUIMTE, Toxicology Laboratory, Biological Sciences Department, Faculty of Pharmacy, University of Porto, Porto, Portugal, 2Federal
University of Health Sciences from Porto Alegre, Porto Alegre, Brazil, 3Department of Legal Medicine, Faculty of Medicine, University of Porto,
Porto, Portugal, 4Department of Sciences, Advanced Institute of Health Sciences - North, CESPU, CRL, Gandra, Portugal, 5Institute of Molecular
and Celular Biology & Laboratory of Biochemistry, Biological Sciences Department, Faculty of Pharmacy, University of Porto, Porto, Portugal,
6CIAFEL, Faculty of Sport Sciences and Physical Education, University of Porto, Porto, Portugal and 7Center for Neurosciences and Cell Biology,
University of Coimbra, Coimbra, Portugal
(Received 5 July 2013; Accepted 10 September 2013)
Abstract: Mitoxantrone (MTX) is an antineoplastic agent that can induce hepato- and haematotoxicity. This work aimed to
investigate the occurrence of cumulative early and late MTX-induced hepatic and haematological disturbances in an vivo model.
A control group and two groups treated with three cycles of 2.5 mg/kg MTX at days 0, 10 and 20 were formed. One of the trea-
ted groups suffered euthanasia on day 22 (MTX22) to evaluate early MTX toxic effects, while the other suffered euthanasia on
day 48 (MTX48), to allow the evaluation of MTX late effects. An early immunosuppression with a drop in the IgG levels was
observed, causing a slight decrease in the plasma total protein content. The early bone marrow depression was followed by signs
of recovery in MTX48. The genotoxic potential of MTX was demonstrated by the presence of several micronuclei in MTX22
leucocytes. Increases in plasma iron and cholesterol levels in the MTX22 rats were observed, while in both groups increases in
the unconjugated bilirubin, C4 complement, and decreases in the triglycerides, alanine aminotransferase, alkaline phosphatase
and transferrin were found in plasma samples. On MTX 48, the liver histology showed more hepatotoxic signs, the hepatic levels
of reduced and oxidized glutathione were increased, and ATP hepatic levels were decreased. However, the hepatic total protein
levels were decreased only in the livers of MTX22 group. Results demonstrated the MTX genotoxic effects, haemato- and direct
hepatotoxicity. While the haematological toxicity is ameliorated with time, the same was not observed in the hepatic injury.
Mitoxantrone (MTX) is an anticancer and immunosuppressive
drug that has been used in the treatment of tumours such as
acute leukaemia, lymphoma, prostatic and breast cancer [1]
and in the active forms of relapsing-remitting or secondary
progressive multiple sclerosis [2]. MTX acts as an intercalat-
ing agent that causes double breaks in DNA by stabilization
of a complex formed between DNA and topoisomerase II
[1,3]. The regimen of MTX administration varies depending
on disease progression and the clinical condition of the
patient. Additionally, MTX is a substrate of membrane efflux
pumps, namely the transporter breast cancer resistance protein
(BCRP), which could interfere in MTX biodisposition [4].
However, the doses commonly employed range between
12–14 mg/m2 and the maximum recommended cumulative
dose is 140 mg/m2 [1].
One of the most serious adverse events related to MTX
therapy is the late and irreversible cardiotoxicity [1], whose
underlying mechanisms have been studied by us [5–7]. It is
known that cardiotoxic drugs such as MTX can cause acute
liver failure as a result of a primary congestive heart failure
with low cardiac output and consequent reduced hepatic blood
flow [8]. However, the precise origin of liver failure, due to a
direct effect or secondary to the cardiomyopathy, is not easy
to define, because clinical signs of cardiac decompensating
can be undetected in a first moment delaying the diagnosis
[8]. Additionally, MTX has been considered more hepatotoxic
than other antineoplastic agents such as doxorubicin [9].
In human beings, the MTX-induced hepatotoxicity mani-
fests as transient increases in the serum bilirubin concentration
and in the activity of hepatic enzymes, occurring in about
15% of treated patients (12 mg/m2) [2,10]. Indeed, the inhibi-
tion of CYP450 metabolism in HepG2 cells and rat isolated
hepatocytes prevented the MTX cytotoxicity [11], demonstrat-
ing the relevance of MTX oxidative metabolism to its noxious
effects. MTX has at least one pharmacologically and
toxicologically relevant metabolite, naphthoquinoxaline (the 8,
11-dihydroxy-4-[2-hydroxyethyl]-6-[[2-[[2-hydroxyethyl]amino]
ethyl]amino]-1,2,3,4,7,12-hexahydronaphto-[2,3]-quinoxaline-
7-12-dione), which has proven antitumour effects and has
been related to MTX toxicity [5,10]. Recently, we demon-
strated that, as it happens with MTX, the naphthoquinoxaline
metabolite also distributes to highly perfused tissues and accu-
mulates in organs such as liver and heart in rats [5]. The liver
is subjected to a prolonged exposure to MTX and, possibly, to
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this toxic metabolite that may contribute to its direct hepato-
toxicity.
Haematological parameters should be monitored during
therapy and the occurrence of neutropenia and thrombocytope-
nia can limit the dose administered or obligate the cessation of
MTX therapy [1,12], demonstrating the haematological effects
induced by MTX. The late haematological effects of MTX
involves the development of MTX-associated leukaemia,
which is also related to other topoisomerase II inhibitors [1].
Considering that the occurrence of liver dysfunction, as well
as MTX-induced haematological toxicity in the treatment of
complex diseases such as cancer and multiple sclerosis, can
compromise the therapy [13], this work aimed to characterize
the potential hepatotoxicity and haematological toxicity after
therapeutic doses of MTX administration in male Wistar rats
in 2 experimental settings. Animals were subjected to 3 cycles
of 2.5 mg/kg MTX (cumulative dose of 7.5 mg/kg, which cor-
responds to 48 mg/m2 by the allometric relationship). The
toxic effects were evaluated 48 hr (day 22) after the last
administration to assess immediate toxicity and also 28 days
after the last administration (day 48) to determine whether the
effects were cumulative or whether adaptation responses
occurred in the hepatic tissue and blood.
Materials and Methods
Chemicals. All chemicals and reagents were of analytical grade.
MTX hydrochloride, reduced glutathione (GSH), oxidized glutathione
(GSSG), glutathione reductase (GR, EC 1.6.4.2), 2-vinylpyridine,
reduced b-nicotinamide phosphate adenine dinucleotide (b-NADPH),
5,5-dithio-bis(2-nitrobenzoic acid) (DTNB), luciferin and luciferase
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Perchloric
acid (HClO4) was obtained from Merck (Darmstadt, Germany). The
reagents for biochemical analyses were purchased from PZ Cormay
S.A.
Animals. Adult male Wistar rats (Charles River Laboratories,
Barcelona, Spain) weighing 240–300 g were used. The animals were
housed in individual cages, in a temperature- and humidity-controlled
environment and acclimated for 1 week prior to the study. Food and
water were provided ad libitum, and animals were subjected to a 12-hr
light/dark cycle. Animal experiments were approved by the Ethical
Committee of Faculty of Pharmacy of the University of Porto
(protocol number 09/04/2013). Housing and experimental treatment of
the animals were in accordance with the Guide for the Care and Use
of Laboratory Animals from the Institute for Laboratory Research.
The experiments complied with current Portuguese laws.
Dose regimen. Animals were divided into three groups (five animals
per group): control, MTX22 and MTX48. Animals were treated with
three administrations, 5 mL/kg, intraperitoneal, of saline solution
(0.9% NaCl) (control) or MTX 2.5 mg/kg (MTX22 and MTX48) on
days 0, 10 and 20. The MTX-treated groups reached a total
cumulative dose of 7.5 mg/kg on day 20. Animals belonging to the
MTX22 group suffered euthanasia on day 22, to evaluate the early
MTX-induced cumulative damage (i.e. 2 days after the last cycle of
treatment). Animals from the MTX48 group suffered euthanasia on
day 48, corresponding to 28 days after the last administration, to
evaluate late cumulative responses [6]. Two animals of control group
suffered euthanasia on day 22 and the others on day 48.
The used dose of MTX is clinically realistic (2.5 mg/kg corresponds
to 16 mg/m2 of a rat weighing 240 g, being similar to the dose admin-
istered in human beings and about one-tenth of the maximum dose
recommended in human beings). The regimen of administration (one
administration every 10 days) was scheduled aiming to simulate the
human chemotherapeutic cycles. The interval of 10 days was defined
considering the life cycle of the rat and the clinical conditions noted
in pilot studies.
Euthanasia was performed under anaesthesia with xylazine/ketamine
(10 mg/kg and 100 mg/kg), and blood was collected through cardiac
puncture. A necropsy was performed to all animals.
Plasma biochemical analysis. On the day of euthanasia, blood was
collected into heparinized tubes to perform biochemical analysis and
into EDTA tubes to the haematological evaluations. Plasma levels of
albumin, total proteins, IgG, IgM, IgE, C3 and C4 complement, total
and conjugated bilirubin, alanine aminotransferase (ALT), alkaline
phosphatase, transferrin, ferritin, iron, cholesterol, triglycerides,
glucose, amylase, creatinine, urea, uric acid, potassium sodium,
calcium, C-reactive protein, a1–antitrypsin, d-glutamyltranspeptidase
(GGT) and lactate dehydrogenase (LDH) were evaluated in duplicate
on an AutoAnalyzer (PRESTIGE 24i, PZ Cormay S.A.) using the
respective kits and following the manufacturer instructions.
Haematological analysis. Whole blood samples (collected using
EDTA as anticoagulant) were used to evaluate erythrocyte count,
haemoglobin (Hb) concentration, haematocrit, haematological indexes
– mean cell volume (MCV), mean cell haemoglobin (MCH), mean
cell haemoglobin concentration (MCHC), red cell distribution width
(RDW), platelet count (PLT), plateletcrit (PCT), platelet distribution
width (PDW), mean platelet volume (MPV) and total white blood cell
(WBC) count, using an automated blood cell counter (Sysmex K1000,
Hamburg, Germany). Differential leucocyte count was performed on
blood smears stained according to Wright [14]. Reticulocyte count
was performed by microscopic counting on blood smears after vital
staining with new methylene blue (Reticulocyte stain; Sigma-Aldrich).
Tissue preparation for light and transmission electron
microscopy. For light microscopy analysis, pieces of 2–4 mm3 from
all liver lobes were fixed in 4% formaldehyde during 24 hr. The
pieces were further dehydrated with graded ethanol (Panreac,
Barcelona, Spain) and included in paraffin blocks (MERCK) after
standard procedures. Semithin sections (5 lm) were cut (Leica
Microsystems, Model RM2125) and mounted on silane-coated slides
(Sigma-Aldrich). After dewaxed in xylene and hydrated through
graded alcohol concentrations, tissue sections were stained with
haematoxylin-eosin (Atom Scientific Ltd, Manchester, UK) and
analysed under a light microscope coupled to a digital camera (Axio
Imager A1; Carl Zeiss, Oberkochen, Germany).
For transmission electron microscopy, 1 mm3 tissue pieces from all
liver lobes were fixed in 2% glutaraldehyde, post-fixed with 2%
osmium tetroxide, dehydrated in graded ethanol, and later embedded
in Epon (TAAB 812 Resin, Kit Cat. No. T024) according to standard
procedures. Ultrathin (100 nm) sections obtained in an ultra micro-
tome (Reichert Ultracut) were mounted in copper grids (300 Mesh;
from TAAB Laboratories Equipment Ltd, West Berkshire, UK) and
further contrasted with uranyl acetate and lead citrate for analysis at
an accelerating voltage of 60 Kv (Zeiss EM 10A; Carl Zeiss).
Biochemical determinations in the hepatic tissue. After the excision
from each animal, the liver was washed in a phosphate-buffered saline
solution, pH 7.4, dried and weighed to assess the relative mass of the
organ (calculated as a percentage of the total body-weight on the day
of euthanasia). Liver samples were homogenized [1:4 (m/v)] in ice-
cold phosphate-buffered solution, pH 7.4, with an Ultra-Turrax
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homogenizer and centrifuged (3000 9 g, 10 min., 4°C). Aliquots of
the supernatant were taken to determine the glutathione status, ATP
levels and total protein levels.
Total glutathione (GSHt), GSH and GSSG levels in the hepatic
tissue. An aliquot of previous supernatant was added to an equal
volume of HClO4 10% (5% final concentration). Samples were again
homogenized, centrifuged (16 000 9 g, 10 min., 4°C), and the
supernatant was used to determine the glutathione status [15]. The
GSHt and GSSG levels were evaluated by the DTNB-GSSG reductase
recycling assay, as previously described [16,17]. Briefly, for GSHt
quantification, 200 lL of the acidic supernatant was neutralized with
200 lL of 0.76 M KHCO3 and centrifuged (16 000 9 g, 5 min.,
4°C). For GSSG quantification, 10 lL of 2-vinylpyridine was added
to 200 lL of acidic supernatant, and the samples were shaken during
1 hr on ice prior to the neutralization step. In 96-well plates, 100 lL
of sample, standard or blank was added in triplicate and mixed with
65 lL of fresh reagent solution containing DTNB and b-NADPH.
Plates were incubated at 30°C for 15 min. in a plate reader
(PowerWaveX; Bio-Tek Instruments, Winooski, VT, USA) prior to
the addition of 40 lL glutathione reductase solution (10 U/mL). The
final product of this reaction is a coloured substance, and its formation
was monitored for 3 min., at 415 nm, and compared with a standard
curve. GSH and GSSG standard solutions were prepared in HClO4
5% [15]. Results were expressed as nmol/mg protein.
Hepatic ATP levels. An aliquot of the supernatant obtained as
described above was added to an equal volume of HClO4 10% (5%
final concentration). Samples were again homogenized, centrifuged
(16 000 9 g, 10 min., 4°C), and the supernatant was used to
determine the ATP levels as described before [6]. One hundred
microliter of tissue homogenate was neutralized with 100 lL of
0.76 M KHCO3 and centrifuged (16 000 9 g, 10 sec., 4°C). The
ATP levels were quantified by the bioluminescence test after the
reaction of 100 lL neutralized supernatant with luciferin/luciferase
solution. ATP standards were prepared in 5% HClO4. ATP
intracellular levels were normalized to total protein content (nmol/mg
of protein).
Hepatic total protein quantification. An aliquot of the supernatant
obtained after centrifugation described in the section ‘Biochemical
determinations in the hepatic tissue’ was diluted in 0.3 M NaOH and
used to assess the total hepatic protein levels. The protein levels were
determined by the Lowry method using a microplate reader (750 nm),
as previously described [16].
Statistical analysis. Results are presented as means  standard
deviation. Statistical comparisons between groups were performed
with one-way ANOVA (in case of normal distribution: haematological
and plasma biomarkers) or the Kruskal–Wallis test (one-way ANOVA on
ranks – in case of not normal distribution: hepatic protein levels,
hepatic glutathione levels and ATP levels). Significance was accepted
at p values < 0.05. Details of statistical analysis are found in the
legend of the figures in the results section.
Results
Plasma and haematological changes induced by MTX
cumulative doses.
The results from plasma and haematological biomarkers at the
end of the experiment which presented significant changes (in
at least one of the treated groups) compared with control rats,
are shown in Table 1. A transient decrease in total protein and
IgG plasma levels was observed in the MTX22 group. Tran-
sient decreases in RBC count, HCT, Hb, WBC and reticulo-
cytes were evident in the MTX22 group. The leucocyte group
Table 1.
Plasma and haematological parameters of the animals treated with MTX (three cycles of 2.5 mg/kg) and control group.
Parameter
Groups
Control MTX22 MTX48
Total proteins (g/dL) 56.8  3.3 48.3  4.9* 52.4  2.1
IgG 48.6  19.9 10.2  6.5** 32.0  13.9
Complement C4 (mg/dL) 2.4  0.9 4.8  0.5** 3.7  0.6*
Conjugated bilirubin (mg/dL) 0.10  0.02 0.07  0.02* 0.06  0.02*
ALT (U/L) 34.8  7.4 13.0  5.3** 19.5  5.0**
Alkaline phosphatase (U/L) 278.6  61.0 133.2  54.9** 149.0  35.8**
Cholesterol (mg/dL) 44.6  2.8 65.28  11.3** 52.47  7.6
Triglycerides (mg/dL) 93.8  9.9 40.6  7.28*** 64.3  19.5*
Iron (µg/dL) 176.9  27.8 250  27.0** 169.7  14.3
Transferrin (mg/dL) 105.2  5.2 73.6  17.0** 82.7  15.5*
RBC (9106/mm3) 7.8  0.9 6.0  1.0* 6.6  0.6
Haematocrit (%) 43.78  4.9 32.7  5.5* 43.7  3.2
Hb(g/dL) 14.6  1.1 11.4  1.8** 14.4  0.7
MCH (pg) 18.8  0.9 19.1  0.3 22.1  1.2***
RDW (%) 12.5  0.4 12.9  0.9 17.9  1.1***
MCV (fL) 56.2  1.1 54.5  1.3 66.3  2.1***
Platelet (9103/mm3) 599.4  79.24 592.0  246.2 785.0  74.0
MPV (fL) 7.4  0.4 8.4  1.0* 6.9  0.4
Reticulocytes (%) 1.6  0.5 0.0  0.0** 2.9  0.6**
WBC (9103/mm3) 2.8  1.3 1.6  0.8* 2.3  0.7
Results are presented as means  standard deviation.
Statistical analysis was performed using one-way ANOVA followed by the Student Newman Keuls post hoc test (*p < 0.05 versus control,
**p < 0.01 versus control, ***p < 0.001 versus control).
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that mostly contributed to this decrease were lymphocytes
(diminished in both groups). Additionally, increased levels of
MPV were observed in the MTX22 group and microscopic
analysis of the blood smears from the MTX22 group revealed
the presence of several nucleated cells with micronucleus for
all the animals (Fig. 1). Transient bone marrow suppression
was observed in the MTX22 group, as shown by the absence
of circulating reticulocytes. However, in MTX48, a recovery
was observed and circulating reticulocytes were significantly
higher than controls, representing an adaptation process to
MTX exposure (Table 1).
A significant increase in the C4 complement and reduced
levels of transferrin, conjugated bilirubin, ALT and alkaline
phosphatase were evident in both treated groups. The MTX48
group had significant increases in the MCH, RDW and MCV
levels, while WBC returned to control levels at MTX48.
Glucose, amylase, albumin, creatinine, urea, uric acid, cal-
cium, potassium, sodium, C-reactive protein, a1-antitrypsin,
GGT, C3 complement, LDH, total bilirubin and IgM, and IgE
plasma levels in the treated animals did not show any changes
in comparison with control levels (data not shown). PLT,
PCT, MCHC, platelet distribution width, neutrophil,
eosinophil, basophil and monocytes levels remained constant
in all groups at the time-points evaluated.
MTX administration induced macro- and microscopic changes
in hepatic tissue.
Hepatic macroscopic alterations were evident in the necropsy
of MTX-treated rats (Fig. 2). The livers, presenting a dark red
colour with brilliant surface, were swollen with all lobes
showing rounded edges. Their consistency was firm but friable
during the cut. These alterations were more notorious in the
MTX48 group. No macroscopic changes were observed in
control livers.
The microscopic analysis did not reveal any abnormality in
animals from the control group (data not shown). However, at
light microscopy, the MTX22 livers revealed disperse regions
of focal necrosis without changes in the organ architecture
(Fig. 3). The hepatic tissue presented an apparent proliferation
of kupffer cells, hepatocyte oedema in the periportal regions
and enlargement of periportal spaces with cellular infiltration
and collagen deposition (Fig. 3). In the same group, transmis-
sion electron microscopy confirmed the cellular oedema
mainly located in the periportal region. Moreover, an increased
density of lysosomes (Fig. 3) and mild steatosis affecting the
majority of hepatocytes were observed. In general, the hepato-
cytes presented several nucleoli (more than 2–3 per cell) and
abundant rough endoplasmic reticulum, without signs of mito-
chondria swelling. Frequent perisinusoidal cells containing
lipid droplets, suggestive of stellate cells, as well as collagen
fibres proliferation into the Disse spaces, and abundant hepatic
and endothelial microvilli were also observed (Fig. 3).
In the MTX48 group, the periportal cellular oedema appar-
ently decreased when compared with the MTX22 group,
although with an enlargement of periportal spaces and a more
evident fibrotic area. A higher number of areas containing cel-
lular infiltration with apparent mild disorganization of the lob-
ular structure were seen (Fig. 3). In general, the transmission
electron microscopy revealed a high content of lysosomes in
hepatocytes, abundant Kupffer and stellate cells, as well as a
huge proliferation of collagen fibres into the Disse spaces.
Fig. 1. Representative blood smears from the MTX22 group, demon-
strating a monocyte with the presence of a micronucleus (arrow).
Fig. 2. Necropsy of an animal from the MTX48 group, demonstrating
the liver macroscopic alterations observed in all MTX-treated rats,
being more evident in the MTX48 group. The liver presents a swollen
aspect with rounded edges in all lobes, having a dark red colour and
brilliant surface. Male Wistar rats were subjected to MTX treatment
(three cycles of 2.5 mg/kg) and suffered euthanasia 28 days after the
last MTX administration.
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Changes in the hepatic macro- and microscopic architecture
were not accompanied by significant alterations in the hepatic
relative mass (data not shown).
MTX-induced hepatic alterations in the protein levels,
glutathione status and ATP levels.
The hepatic protein levels were significantly decreased in the
MTX22 group (54.1  3.5 mg/g) when compared to control
(107.3  28.6 mg/g). The values observed in the MTX48
group (165.5  91.8 mg/g) suggest a recovery of hepatic pro-
teins, being similar to control values (Fig. 4). Moreover, as
shown in Fig. 5, late significant increases were observed in
the hepatic GSHt levels (47.3  11.0 nmol/mg in the MTX48
group versus 26.3  7.6 nmol/mg and 25.4  3.6 nmol/mg
in the control and MTX22 groups, respectively). This increase
in GSHt corresponds to the late increase in the GSH
(37.4  8.5 nmol/mg in the MTX48 group compared with
22.9  7.7 nmol/mg in the control and 19.5  2.5 nmol/mg
in the MTX22 group), and a great increase in the GSSG levels
in the MTX48 group (4.9  1.3 nmol/mg versus
1.7  0.3 nmol/mg in the control and 2.9  1.1 nmol/mg in
the MTX22 group). Regarding hepatic ATP levels, a signifi-
cant decrease in the MTX48 group (5.2  1.5 nmol/mg) com-
pared with control (10.1  1.5 nmol/mg) or MTX22
(9.0  1.5 nmol/mg) groups was seen (Fig. 6).
Discussion
This work aimed to investigate the potential hepatotoxicity
and haematotoxicity of MTX using a multiple dose in vivo
model. To evaluate whether the toxic effects were also cumu-
lative and long-lasting, as it happens in some cardiac events,
two time-points were selected: 2 and 28 days after the last
administration of MTX. The choice of two different time-
points represented by the MTX22 and MTX48 groups is
A
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Fig. 3. Light (A, B and C) and electron micrographs (D, E, F and G) of liver sections illustrating the structural and ultrastructure alterations
observed in MTX-treated animals. In (A) (from MTX22 group), two central veins (*) surrounded by hepatocytes displaying a normal morphology
are seen; however, at the periphery of the lobule, the presence of swollen hepatocytes is notorious (#); (B) (from MTX48) depicts a necrotic area
(*) infiltrated by fibroblasts like cells with deposition of connective tissue (arrows); (C) (from MTX48 group) displays a portal area with enlarge-
ment of periportal space, which is invaded by connective tissue and infiltrated by fibroblasts like cells and leucocytes; (D) (from MTX22 group)
depicts a great amount of lysosomes within a hepatocyte (arrows), with mitochondria presenting a normal morphology without signals of swelling;
In (E) (from MTX22 group), the presence of collagen fibres (*) in the Disse space as well as an area of high density of hepatocyte microvilli are
shown (#); (F) (from MTX22 group) shows two adjacent swollen hepatocytes, containing mitochondria with normal morphology (at left and right
sides), separated by a space occupied by abundant microvilli (#) with a Kupffer cell near by (arrow); at the centre, a stellate-like cell (*) with
several lipid droplets; In (G) (from the MTX48 group), a stellate cell is depicted.
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Fig. 4. Hepatic protein levels of the animals treated with MTX (three
cycles of 2.5 mg/kg) and control group. Results are presented as
means  standard deviation. Statistical analysis was performed using
Kruskal–Wallis test (ANOVA on ranks) followed by the Student New-
man Keuls post hoc test (*p < 0.05 versus control).
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important to evaluate acute/adaptive and transient/ultimate
effects of the liver or haematological function, because they
present high turnover and plasticity [13].
We observed hepatotoxicity and haematological toxic
effects after MTX administration to rats, as demonstrated by
the macro- and microscopic changes in the hepatic architec-
ture (Figs 2 and 3), and by several haematological altera-
tions (Table 1). The reduction in hepatic protein levels in
the MTX22 group, the late increases in the GSHt hepatic
levels, demonstrated by an increase in GSH and GSSG con-
tents, and late decreases in the hepatic ATP values in the
MTX48 group showed mechanistic responses of hepatic tis-
sue after MTX administration (Figs 4–6, respectively).
The MTX-induced haematological toxic effects were dem-
onstrated by an early bone marrow depression on MTX22
group (Table 1) followed by signals of haematopoiesis recov-
ery, observed in the MTX48 group. Indeed, MTX22 presented
a reduction in WBCs, RBCs and reticulocytes, associated with
an increase in non-conjugated bilirubin that was followed, at
MTX48, by a recovery of WBCs and RBCs. The return to
basal values of RBCs at MTX48 was probably due to a signif-
icant increase in reticulocytes, leading to macrocytosis and
anisocytosis, as shown by the significant increase in the RDW
and in MCV. Additionally, increased levels of plasma iron
suggest an increase in iron absorption to overcome the initial
reduction in RBCs. These results are in accordance with what
has been observed in human beings and justify the importance
of monitoring haematological parameters during MTX chemo-
therapy [1]. In fact, the MTX-induced myelosuppression mani-
fests mostly as leukopaenia, thus being the main dose-limiting
effect that occurs shortly after MTX treatment [18]. Also, in
human beings, after administration of MTX (38 mg/m2), the
WBC counting returned to normal values within 7 days [18].
However, patients treated with higher dose regimens tend to
present an even faster blood count recovery [1]. The presence
of micronucleus in MTX22 blood smears (Fig. 1) was con-
stant in all animals from this treated group, suggesting a geno-
toxic potential for MTX. Altogether, these data elucidate the
rational for continued blood cell counts after MTX-therapy
cessation due to the risk of MTX-associated secondary acute
leukaemia [2]. As for other topoisomerase II inhibitors, there
are only limited data on the MTX genotoxicity using micro-
bial conventional assays [10]. However, it is well known that
Co
ntr
ol
MT
X2
2
MT
X4
8
Co
ntr
ol
MT
X2
2
MT
X4
8
Co
ntr
ol
MT
X2
2
MT
X4
8
0
20
40
60
80
**
Total glutathione
G
SH
t l
ev
el
s
(n
m
ol
/m
g 
pr
ot
ei
n)
Reduced glutathione
0
10
20
30
40
50 *
G
SH
 le
ve
ls
(n
m
ol
/m
g 
pr
ot
ei
n)
Oxidized glutathione
0
2
4
6
8
**
G
SS
G
 le
ve
ls
(n
m
ol
/m
g 
pr
ot
ei
n)
A B
C
Fig. 5. Hepatic (A) GSHt, (B) GSH and (C) GSSG levels of the animals treated with MTX and control group. Results are presented as
means  standard deviation. Statistical analysis was performed using the Kruskal–Wallis test (ANOVA on ranks) followed by the Student Newman
Keuls post hoc test (*p < 0.05 versus control).
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Fig. 6. Hepatic ATP levels of the animals treated with MTX and con-
trol group. Results are presented as means  standard deviation. Sta-
tistical analysis was performed using the Kruskal–Wallis test (ANOVA
on ranks) followed by the Student Newman Keuls post hoc test
(*p < 0.05 versus control).
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MTX causes single and double breaks in the DNA [1,3] and
also affects the cell cycle at various stages [3,19].
As stated before, MTX is an immunosuppressive drug that
promotes apoptosis in antigen-presenting cells and reduces the
levels of all types of immune cells [2,20]. Accordingly, we
observed a transient decrease in the plasma IgG levels in the
MTX22 rats (Table 1). Another study assessing the human
safety of MTX, rituximab, ifosfamide and etoposide combined
therapy demonstrated significant decrease in the IgG levels in
patients treated for non-Hodgkin’s lymphoma [21]. The IgG is
synthesized by blood cells and corresponds to about 80% of
total immunoglobulin [22]. Thus, the significant decreases in
IgG levels in the MTX22 group may correlate with the
observed decreases in the plasma total protein levels observed
in this group. The levels of the main plasma protein albumin
remained constant in the MTX-treated groups (data not
shown).
The MTX-induced hepatotoxicity was clearly demonstrated
by the macroscopic changes observed in the MTX-treated liv-
ers (Fig. 2). Signals of hepatic injury were found in the earlier
time-point (MTX22 group), notably by changes in plasma-
related liver parameters, in the hepatic macro- and microscopic
changes (Fig. 3) and by alterations in biochemical hepatic
values (Fig. 4). These data suggest hepatic dysfunction, dem-
onstrated by the decrease in plasma enzyme levels, protein
turn-over and higher free cholesterol. The impairment of hepa-
tic function in both treated groups is also shown by decreases
in the plasma triglycerides, which are mainly synthesized by
the hepatocytes (Table 1). Furthermore, the increase in the
plasma cholesterol levels in the MTX22 group is consistent
with the mild steatosis observed by structural analysis, which
can be related to the decreased hepatic synthesis of lipopro-
teins. The diminished hepatic protein synthesis was demon-
strated by lower protein hepatic levels (MTX22), and lower
levels of plasma biochemical parameters such as ALT, alka-
line phosphatase and transferrin in both MTX-treated groups.
In fact, in human beings, the acute hepatotoxicity of MTX
manifests as transient increases in serum bilirubin levels and
in the activity of liver enzymes [10]. However, decreases in
the hepatic synthesis of these enzymes are considered a result
of (sub)chronic hepatotoxicity observed with other xenobiotics
[23–26]. Possibly due to the marked decrease in protein turn-
over, MTX22 hepatocytes show large nucleoli and abundant
rough endoplasmic reticulum, as a compensation mechanism
to attempt restoring hepatic synthesis diminished by the action
of the drug. The apparent recover of the hepatic total protein
levels (Fig. 4) on MTX48 compared with MTX22 does not
mean total functional gain, considering the changes in MTX48
hepatic ATP, glutathione and plasma protein levels.
Moreover, increases in the unconjugated bilirubin in both
treated groups are suggestive of impaired conjugation with
glucuronides. Subclinical unconjugated hyperbilirubinaemia is
related to antituberculosis therapy, and it is attributed to the
inhibition of the bile salt exporter pumps [26]. Microscopic
hepatic evaluations (Fig. 3) demonstrated a huge proliferation
in the Kupffer cells, leucocyte infiltration and collagen deposi-
tion, which are indicative of an inflammatory process. Indeed,
it might be related to the notorious increases observed in the
plasma C4 complement levels because this component is syn-
thesized by Kupffer cells [27]. The hepatic microscopic
changes were more notorious at a later time-point (MTX48
group). As already mentioned, MTX and naphthoquinoxaline
(an active metabolite) are retained in the hepatic tissue [5,28],
and the continued hepatic exposure may result in hepatic
injury. Recently, we described some significant changes
related to cardiotoxicity in the MTX22 group (decreased levels
of CK, CK-MB, increased cardiac relative mass and adaptive
increase in the mitochondrial complexes IV and V). However,
it was demonstrated that the cardiac energetic damage was
established at a later time-point (increased levels of plasma
lactate and cardiac relative mass, decrease in the mitochondrial
complex V activity with consequent depletion of cardiac ATP
levels) [6]. One hypothesis for the MTX-induced hepatotoxic-
ity is that it was secondary to the concomitant MTX-induced
cardiotoxicity. However, microscopic data do not support the
theory that the classic late cardiotoxicity of MTX [6] may
contribute to promote a secondary hepatic lesion [8] consider-
ing the absence of significant centrilobular damage or dilata-
tion of centrilobular sinusoids by blood congestion. In another
study, the hepatic histophatological results of mice treated
with MTX (15 mg/kg) demonstrated intense hydropic vacuoli-
zation of the cytoplasm, necrosis areas, picnosis and nuclear
lysis not recovered until 5 days after the single dose adminis-
tration [9]. Accordingly, in the present study, the MTX-
induced hepatic damage continued until the end of the evalua-
tions.
Oxidative stress seems to assume a more important role
in the MTX hepatotoxicity when compared to the oxidative
damage observed in the MTX-related cardiomyopathy [6,7].
Increases in the hepatic levels of GSHt were observed in
the MTX48 group. As shown in Fig. 5, this increase is
related to a slight (but significant) increase in the GSH
hepatic levels and GSSG levels. Increases in the GSH might
be interpreted as an attempt to enhance the antioxidant con-
tent to respond to injury, while increased levels of GSSG
are a clear sign of oxidative stress. It is known that Kupffer
cells, which were abundantly present in the MTX48 livers,
are a source of reactive oxygen and nitrogen species [29].
The link between oxidative stress and the MTX-induced
hepatic damage was already suggested in a study with mice,
where the administration of MTX (15 mg/kg) caused
increases in the lipid peroxidation, decreases in the antioxi-
dant enzymes (superoxide dismutase, catalase and glutathione
peroxidase) and depletion of the hepatic retinol and GSH
content [9]. Moreover, the incubation of MTX (100 lM)
with HepG2 cells for 6 hr was enough to promote the
decrease in the GSH levels [30]. The apparent contradiction
between our results (increased in the GSH hepatic levels)
and the previously reported data (decreases in the GSH con-
tent) may be explained by the differences in the experimen-
tal design or models. Both referred studies assessed the
GSH levels 3, 4 and 5 days after MTX administration [9]
or 6 hr after high MTX concentration incubation [30]. In
the present study, significant changes in the glutathione sta-
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tus were seen only at the last evaluated time-point, 28 days
after the last dose administration. Hence, the organism is
subjected to compensatory/adaptive effects favoured by the
elapsed time between the last MTX administration and rat
euthanasia.
To the best of our knowledge, it is the first time that late
hepatic energetic imbalance is associated with MTX-induced
hepatotoxicity. The decrease in the hepatic ATP levels
observed in the MTX48 group (Fig. 6) occurred 28 days after
the last MTX administration. One can speculate about this
result. Decreases in the ATP hepatic levels are observed in the
human non-alcoholic steatohepatitis [31], and are associated
with covalent binding of drugs with intracellular proteins [32].
As already stated, MTX and its toxic known metabolite accu-
mulates in the liver tissue [5,28] and its long-lasting effects
can be attributed to MTX persistence in the cells and its
strong affinity for cellular macromolecules and membranes
[33]. Additionally, the ATP decreases can be related to mito-
chondrial disruption. In other models related to myocytes, the
MTX-induced decreases in the ATP levels have already been
described [6,7,34]. In these models, the observed cardiac ener-
getic depletion was already attributed to the mitochondrial tox-
icity induced by MTX, affecting the ATP synthesis through
perturbations in the mitochondrial membrane potential and late
inhibition of ATP synthase activity in vitro and in vivo [6,7].
Moreover, in a work by Shipp et al. [34], the MTX-metabolite
naphthoquinoxaline also disrupted ATP homeostasis in neona-
tal rat heart cells. Although, in the present study, mitochon-
drial morphologic changes in the hepatic tissue were not
observed, one cannot exclude the existence of functional mito-
chondrial disturbances.
In summary, this study allowed to better understand the
long-term effect of MTX treatment. Moreover, the intrinsic
hepatotoxic potential of chemotherapy is of great concern
because an altered hepatic function might decrease the cancer
therapy effectiveness and/or increase toxic adverse effects
[13]. In this study, we described a severe hepatotoxicity. We
did not find hepatic changes suggestive of heart failure and
the location of the histological findings in the periportal region
seem to reinforce the direct hepatotoxic potential of MTX.
After 28 days of the last MTX cycle, hepatic tissue remained
with reduced levels of glutathione and ATP, which are essen-
tial for the hepatic function.
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